5324882022-04-012022-06-305324882022-04-012022-06-30in-bse-fin:OtherExpenses1Member5324882022-04-012022-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882022-04-012022-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532488DIVISLABNOTLISTEDINE361B01024Divi's Laboratories LimitedEquity2022-04-012023-03-312022-08-122022-07-28INRLakhsFirst quarterSingle segmentPharmaceuticals2022-08-1211:00:002022-08-1212:15:00Not applicable2022-04-012022-06-30UnauditedConsolidated225452000008839000002342910000077855000004420000028990000024638000001300000836600000349480000014916100000851300000008513000000135560000013730000014929000000702010000000007020100000423000007062400000702010000070624000000530900000226.4426.440026.4426.440001.The above Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2022 (“Statement’) is prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors of the Company at its meeting held on 12th August, 2022. The Statement is subjected to ‘limited review’ by the Auditors of the Company and their report contains no qualification. <BR> 2.The consolidated financial results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG. <BR> 3.The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS108. <BR> 4.The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. <BR> 5.The Company has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to Covid-19 pandemic. As the pandemic continues to evolve, the Company will continue to closely monitor for any material changes to future economic conditions. <BR> 6.Forex gain,included in Other Income, for the respective periods is given below: <BR> ( in lakhs) <BR> Quarter Ended Year Ended <BR> 30.06.2022 31.03.2022 30.06.2021 31.03.2022 <BR> Forex gain 5640 3116 1964 4058 <BR> 7.*Figures for the quarter ended 31.03.2022 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year. <BR> <BR> <BR> Other Expenses3494800000Gain on Remeasurement of post-employment benefit obligations840000084000001800000Exchange differences in translating the financial statements of a foreign operation43200000432000007500000